Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Next Previous
X
Search
Trial Profile

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lazertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Acronyms LASER201
  • Sponsors Janssen Research & Development; Yuhan

    • Most Recent Events

    • 01 Apr 2024 Results from long term follow up published in the Lung Cancer
    • 24 Oct 2023 Results (n=332) of an integrated analysis characterizing clinical features of paresthesia and related AEs, and examined effect of lazertinib dose reduction (DR) on drug exposure, safety and clinical efficacy presented at the 48th European Society for Medical Oncology Congress
    • 01 Jan 2023 Results assessing Effects of food and race on the pharmacokinetics of lazertinib (from 3 studies NCT03556436: Healthy subjects N = 24; NCT03046992 n=30 Asian subjects and NCT04075396, n=22 non Asian patients NSCLC patients ) in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer published in the Lung Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top